CD36 and atherosclerosis

Current Opinion in Lipidology

Volumn 11, Issue 5, 2000, Pages 483-491

  Silverstein, Roy L ^a   Febbraio, Maria ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD36 ANTIGEN; SCAVENGER RECEPTOR; TRANSFORMING GROWTH FACTOR BETA;

ANGIOGENESIS; ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOMYOPATHY; CELL ADHESION; DIABETES MELLITUS; FATTY ACID TRANSPORT; HUMAN; INFLAMMATION; LIPID METABOLISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, CD36; ARTERIOSCLEROSIS; CELL ADHESION; HUMANS; INFLAMMATION; LIPID METABOLISM; MEMBRANE PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, IMMUNOLOGIC; RECEPTORS, LIPOPROTEIN; RECEPTORS, SCAVENGER; SCAVENGER RECEPTORS, CLASS B; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 0033775657     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200010000-00006     Document Type: Review

References (108)

1. Platelet glycocalicin. Orientation of glycoproteins of the human platelet surface
2. Effects of thrombin, chymotrypsin and aggregated immunoglobulins on the proteins of the human platelet membrane
3. Classification of human lymphocytes and monocytes with the OK series of monoclonal antibodies
4. A monoclonal antibody against an erythrocyte ontogenic antigen identifies fetal and adult erythroid progenitors
5. Cloning of a rat adipocyte membrane protein implicated in binding or transport of long-chain fatty acids that is induced during preadipocyte differentiation. Homology with human CD36
6. Putative membrane fatty acid translocase and cytoplasmic fatty acid-binding protein are co-expressed in rat heart and skeletal muscles
7. CD36 participates in the phagocytosis of rod outer segments by retinal pigment epithelium
8. Expression of thrombospondin (TSP1) and its receptors (CD36 and CD51) in normal, hyperplastic, and neoplastic human breast
9. Thrombospondin binds to monocytes macrophages and mediates platelet-monocyte adhesion
10. Glycoprotein IV mediates thrombospondin-dependent platelet-monocyte and platelet-U937 cell adhesion
11. CD36 directly mediates cytoadherence of Plasmodium falciparum parasitized erythrocytes
12. Identification of a platelet membrane glycoprotein as a falciparum malaria sequestration receptor
13. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1
14. CD36 is a receptor for oxidized low density lipoprotein
15. Role of membrane-associated and cytoplasmic fatty acid-binding proteins in cellular fatty acid metabolism
16. Muscle-specific overexpression of FAT/CD36 enhances fatty acid oxidation by contracting muscle, reduces plasma triglycerides and fatty acids, and increases plasma glucose and insulin
17. CD36 mediates long-chain fatty acid transport in human myocardium: Complete myocardial accumulation defect of radiolabeled long-chain fatty acid analog in subjects with CD36 deficiency
18. Thrombospondin cooperates with CD36 and the vitronectin receptor in macrophage recognition of neutrophils undergoing apoptosis
19. Recognizing death: The phagocytosis of apoptotic cells
20. Gene encoding the collagen type I and thrombospondin receptor CD36 is located on chromosome 7q11.2
21. Identification of Cd36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats
22. The Mouse Genome Database (MGD): Expanding genetic and genomic resources for the laboratory mouse
23. The CD36, CLA-1 (CD36L1), and LIMPII (CD36L2) gene family: Cellular distribution, chromosomal location, and genetic evolution
24. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor
25. Croquemort, a novel Drosophila hemocyte/macrophage receptor that recognizes apoptotic cells
26. A carboxyl terminal truncation mutant of CD36 is secreted and binds thrombospondin: Evidence for a single transmembrane domain
27. Purification of the major substrate for palmitoylation in rat adipocytes: N-terminal homology with CD36 and evidence for cell surface acylation
28. Analysis of CD36 binding domains: Ligand specificity controlled by dephosphorylation of an ectodomain
29. Characterization of caveolin-rich membrane domains isolated from an endothelial-rich source: Implications for human disease
30. High density lipoprotein prevents oxidized low density lipoprotein-induced inhibition of endothelial nitricoxide synthase localization and activation in caveolae
31. CD36 induction on human monocytes upon adhesion to tumor necrosis factor-activated endothelial cells
32. Regulation of monocyte CD36 and thrombospondin-1 expression by soluble mediators
33. Regulated expression of CD36 during monocyte-to-macrophage differentiation: Potential role of CD36 in foam cell formation
34. Native and modified low density lipoproteins increase the functional expression of the macrophage class B scavenger receptor, CD36
35. Lipoproteins modulate expression of the macrophage scavenger receptor
36. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma
37. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL
38. Induction of CD36 expression by oxidized LDL and IL-4 by a common signaling pathway dependent on protein kinase C and PPAR-gamma
39. Cellular cholesterol regulates expression of the macrophage type B scavenger receptor, CD36
40. Transforming growth factor-beta1 (TGF-beta1) and TGF-beta2 decrease expression of CD36, the type B scavenger receptor, through mitogen-activated protein kinase phosphorylation of peroxisome proliferator-activated receptor-gamma
41. CD36, a novel receptor for oxidized low-density lipoproteins, is highly expressed on lipid-laden macrophages in human atherosclerotic aorta
42. Expression of macrophage (Mphi) scavenger receptor, CD36, in cultured human aortic smooth muscle cells in association with expression of peroxisome proliferator activated receptor-gamma, which regulates gain of Mphi-like phenotype in vitro, and its implication in atherogenesis
43. Regulation of FAT/CD36 gene expression: Further evidence in support of a role of the protein in fatty acid binding/transport
44. Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue- and inducer-specific manner
45. Heart CD36 expression is increased in murine models of diabetes and in mice fed a high fat diet
46. BRL 49653 blocks the lipolytic actions of tumor necrosis factor-alpha: A potential new insulin-sensitizing mechanism for thiazolidinediones
47. The other side of scavenger receptors: Pattern recognition for host defense
48. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes
49. Binding of anionic phospholipids to retinal pigment epithelium may be mediated by the scavenger receptor CD36
50. The class B scavenger receptors SR-BI and CD36 are receptors for anionic phospholipids
51. The pathogenesis of atherosclerosis: A perspective for the 1990s
52. High affinity saturable uptake of oxidized low density lipoprotein by macrophages from mice lacking the scavenger receptor class A type I/II
53. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice
54. Oxidized LDL binds to CD36 on human monocyte-derived macrophages and transfected cell lines. Evidence implicating the lipid moiety of the lipoprotein as the binding site
55. Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species
56. Reduced uptake of oxidized low density lipoproteins in monocyte-derived macrophages from CD36-deficient subjects
57. Recombinant glutathione S-transferase/CD36 fusion proteins define an oxidized low density lipoprotein-binding domain
58. Recombinant GST/CD36 fusion proteins define a thrombospondin binding domain. Evidence for a single calcium-dependent binding site on CD36
59. Expression of the CD36 homolog (FAT) in fibroblast cells: Effects on fatty acid transport
60. Membrane proteins implicated in long-chain fatty acid uptake by mammalian cells: CD36, FATP and FABPm
61. How are free fatty acids transported in membranes? Is it by proteins or by free diffusion through the lipids?
62. Genetics of CD36 and the clustering of multiple cardiovascular risk factors in spontaneous hypertension
63. A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism
64. Human CD36 is a high affinity receptor for the native lipoproteins HDL, LDL, and VLDL
65. Comparison of class B scavenger receptors, CD36 and scavenger receptor BI (SR-BI), shows that both receptors mediate high density lipoprotein-cholesteryl ester selective uptake but SR-BI exhibits a unique enhancement of cholesteryl ester uptake
66. Lysosomal integral membrane protein II binds thrombospondin-1. Structure-function homology with the cell adhesion molecule CD36 defines a conserved recognition motif
67. Identification of a CD36-related thrombospondin 1-binding domain in HIV-1 envelope glycoprotein gp120: Relationship to HIV-1-specific inhibitory factors in human saliva
68. The structural and functional properties of thrombospondin
69. Immunolocalization of thrombospondin-1 in human atherosclerotic and restenotic arteries
70. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1
71. The p53 tumor suppressor gene inhibits angiogenesis by stimulating the production of thrombospondin
72. CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells
73. Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat
74. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin
75. Inhibition of angiogenesis in human glioblastomas by chromosome 10 induction of thrombospondin-1
76. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity
77. A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1
78. The modulation of thrombospondin and other naturally occurring inhibitors of angiogenesis during tumor progression
79. Thrombospondins
80. Integrin-associated protein is a receptor for the C-terminal domain of thrombospondin
81. The thrombospondin receptor integrin-associated protein (CD47) functionally couples to heterotrimeric Gi
82. Interaction of recombinant procollagen and properdin modules of thrombospondin-1 with heparin and fibrinogen/fibrin
83. A single chain 19-kDa fragment from bovine thrombospondin binds to type V collagen and heparin
84. The platelet glycoprotein thrombospondin binds specifically to sulfated glycolipids
85. Identification of integrin alpha 3 beta 1 as a neuronal thrombospondin receptor mediating neurite outgrowth
86. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice
87. Isolation of a somatic cell mutant resistant to the induction of apoptosis by oxidized low density lipoprotein
88. Immunosuppressive effects of apoptotic cells
89. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF
90. 2
91. Transforming growth factor-beta complexes with thrombospondin
92. The type 1 repeats of thrombospondin 1 activate latent transforming growth factor-beta
93. Activation of latent TGF-beta by thrombospondin-1: Mechanisms and physiology
94. Thrombospondin-1 is a major activator of TGF-beta 1 in vivo
95. Activation of rat alveolar macrophage-derived latent transforming growth factor beta-1 by plasmin requires interaction with thrombospondin-1 and its cell surface receptor, CD36
96. Activation of platelet transforming growth factor-beta 1 in the absence of thrombospondin-1
97. A platelet membrane glycoprotein (GP) deficiency in healthy blood donors: Naka-platelets lack detectable GPIV (CD36)
98. Incidence of the Nak(a)-negative platelet phenotype in African Americans is similar to that of Asians
99. CD36 abnormality and impaired myocardial long-chain fatty acid uptake in patients with hypertrophic cardiomyopathy
100. Is CD36 deficiency an etiology of hereditary hypertrophic cardiomyopathy?
101. Myocardial CD36 expression and fatty acid accumulation in patients with type I and II CD36 deficiency
102. Hypertrophic cardiomyopathy with type I CD36 deficiency
103. Scintigraphic evidence for a specific long-chain fatty acid transporting system deficit and the genetic background in a patient with hypertrophic cardiomyopathy
104. Myocardial CD36 expression and fatty acid accumulation in patients with type I and II CD36 deficiency
105. CD36 mediates long-chain fatty acid transport in human myocardium: Complete myocardial accumulation defect of radiolabeled long-chain fatty acid analog in subjects with CD36 deficiency
106. Enhanced myocardial glucose use in patients with a deficiency in long-chain fatty acid transport (CD36 deficiency)
107. Absent myocardial I-123 BMIPP uptake in a family